HDAC family: What are the cancer relevant targets?

Cancer Letters

Volumn 277, Issue 1, 2009, Pages 8-21

  Witt, Olaf ^a,b   Deubzer, Hedwig E ^a,b   Milde, Till ^a,b   Oehme, Ina ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Cancer; Development; HDAC; HDAC inhibitor; Histone deacetylase; Therapy

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; APICIDIN; BELINOSTAT; DEPSIPEPTIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NCT 10A 14A; PANBINOSTAT; PCI 24781; PCI 34051; PYRIDINIUM DERIVATIVE; R 306465; SB 379278A; SB 429201; SHI 12; TRAPOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; DRUG MECHANISM; DRUG TARGETING; EMBRYO DEATH; ENZYME INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ANIMALIA; MUS;

EID: 61849144810     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.016     Document Type: Review

References (122)

1. Taunton J., Hassig C.A., and Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272 (1996) 408-411
2. Rundlett S.E., Carmen A.A., Kobayashi R., Bavykin S., Turner B.M., and Grunstein M. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc. Natl. Acad. Sci. USA 93 (1996) 14503-14508
3. Marks P.A., and Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25 (2007) 84-90
4. Bruserud O., Stapnes C., Ersvaer E., Gjertsen B.T., and Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 8 (2007) 388-400
5. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370 (2003) 737-749
6. Gregoretti I.V., Lee Y.M., and Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338 (2004) 17-31
7. Yang X.J., and Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9 (2008) 206-218
8. Huang Y., Myers S.J., and Dingledine R. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat. Neurosci. 2 (1999) 867-872
9. Ahringer J. NuRD and SIN3 histone deacetylase complexes in development. Trends Genet. 16 (2000) 351-356
10. Wen Y.D., Perissi V., Staszewski L.M., Yang W.M., Krones A., Glass C.K., Rosenfeld M.G., and Seto E. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. USA 97 (2000) 7202-7207
11. McKinsey T.A., Zhang C.L., Lu J., and Olson E.N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408 (2000) 106-111
12. Verdin E., Dequiedt F., and Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet. 19 (2003) 286-293
13. Vega R.B., Harrison B.C., Meadows E., Roberts C.R., Papst P.J., Olson E.N., and McKinsey T.A. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell. Biol. 24 (2004) 8374-8385
14. Chang S., Bezprozvannaya S., Li S., and Olson E.N. An expression screen reveals modulators of class II histone deacetylase phosphorylation. Proc. Natl. Acad. Sci. USA 102 (2005) 8120-8125
15. Berdeaux R., Goebel N., Banaszynski L., Takemori H., Wandless T., Shelton G.D., and Montminy M. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat. Med. 13 (2007) 597-603
16. Kim M.A., Kim H.J., Brown A.L., Lee M.Y., Bae Y.S., Park J.I., Kwak J.Y., Chung J.H., and Yun J. Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif. Exp. Mol. Med. 39 (2007) 205-212
17. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., and Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 417 (2002) 455-458
18. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., and Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18 (2005) 601-607
19. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., and Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115 (2003) 727-738
20. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447 (2007) 859-863
21. Dokmanovic M., Clarke C., and Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5 (2007) 981-989
22. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 (1997) 595-606
23. Luo J., Su F., Chen D., Shiloh A., and Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408 (2000) 377-381
24. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., Schuettengruber B., Hauser C., Brunmeir R., Jenuwein T., and Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21 (2002) 2672-2681
25. Montgomery R.L., Davis C.A., Potthoff M.J., Haberland M., Fielitz J., Qi X., Hill J.A., Richardson J.A., and Olson E.N. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21 (2007) 1790-1802
26. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., Floss T., Goettlicher M., Noppinger P.R., Wurst W., Ferrari V.A., Abrams C.S., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity. Nat. Med. 13 (2007) 324-331
27. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., and Hiebert S.W. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol. Cell 30 (2008) 61-72
28. Knutson S.K., Chyla B.J., Amann J.M., Bhaskara S., Huppert S.S., and Hiebert S.W. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 27 (2008) 1017-1028
29. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., McAnally J., Pomajzl C., Shelton J.M., Richardson J.A., Karsenty G., and Olson E.N. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119 (2004) 555-566
30. Arnold M.A., Kim Y., Czubryt M.P., Phan D., McAnally J., Qi X., Shelton J.M., Richardson J.A., Bassel-Duby R., and Olson E.N. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev. Cell 12 (2007) 377-389
31. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., and Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 24 (2004) 8467-8476
32. Chang S., Young B.D., Li S., Qi X., Richardson J.A., and Olson E.N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126 (2006) 321-334
33. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., and Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110 (2002) 479-488
34. Zhang Y., Kwon S., Yamaguchi T., Cubizolles F., Rousseaux S., Kneissel M., Cao C., Li N., Cheng H.L., Chua K., Lombard D., Mizeracki A., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 28 (2008) 1688-1701
35. Kwon S., Zhang Y., and Matthias P. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev. 21 (2007) 3381-3394
36. Ropero S., Fraga M.F., Ballestar E., Hamelin R., Yamamoto H., Boix-Chornet M., Caballero R., Alaminos M., Setien F., Paz M.F., Herranz M., Palacios J., et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38 (2006) 566-569
37. Park J.M., Lee G.Y., Choi J.E., Kang H.G., Jang J.S., Cha S.I., Lee E.B., Kim S.G., Kim C.H., Lee W.K., Kam S., Kim D.S., et al. No association between polymorphisms in the histone deacetylase genes and the risk of lung cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1841-1843
38. Cebrian A., Pharoah P.D., Ahmed S., Ropero S., Fraga M.F., Smith P.L., Conroy D., Luben R., Perkins B., Easton D.F., Dunning A.M., Esteller M., et al. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 27 (2006) 1661-1669
39. Ozdag H., Teschendorff A.E., Ahmed A.A., Hyland S.J., Blenkiron C., Bobrow L., Veerakumarasivam A., Burtt G., Subkhankulova T., Arends M.J., Collins V.P., Bowtell D., et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7 (2006) 90
40. Park B.L., Kim Y.J., Cheong H.S., Lee S.O., Han C.S., Yoon J.H., Park J.H., Chang H.S., Park C.S., Lee H.S., and Shin H.D. HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem. Biophys. Res. Commun. 363 (2007) 776-781
41. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
42. Choi J.H., Kwon H.J., Yoon B.I., Kim J.H., Han S.U., Joo H.J., and Kim D.Y. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. 92 (2001) 1300-1304
43. Weichert W., Roske A., Gekeler V., Beckers T., Ebert M.P., Pross M., Dietel M., Denkert C., and Rocken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 9 (2008) 139-148
44. Miyake K., Yoshizumi T., Imura S., Sugimoto K., Batmunkh E., Kanemura H., Morine Y., and Shimada M. Expression of hypoxia-inducible factor-1α, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36 (2008) e1-e9
45. Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F.R., Niesporek S., Denkert C., Dietel M., and Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98 (2008) 604-610
46. Weichert W., Roske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., Gekeler V., Boehm M., Beckers T., and Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 14 (2008) 1669-1677
47. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., and Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59 (2004) 177-189
48. Rikimaru T., Taketomi A., Yamashita Y., Shirabe K., Hamatsu T., Shimada M., and Maehara Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72 (2007) 69-74
49. Sasaki H., Moriyama S., Nakashima Y., Kobayashi Y., Kiriyama M., Fukai I., Yamakawa Y., and Fujii Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 46 (2004) 171-178
50. Krusche C.A., Wulfing P., Kersting C., Vloet A., Bocker W., Kiesel L., Beier H.M., and Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 90 (2005) 15-23
51. Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., Hamaguchi M., Hara Y., Kobayashi S., and Iwase H. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res. Treat. 94 (2005) 11-16
52. Glaser K.B., Li J., Staver M.J., Wei R.Q., Albert D.H., and Davidsen S.K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310 (2003) 529-536
53. Senese S., Zaragoza K., Minardi S., Muradore I., Ronzoni S., Passafaro A., Bernard L., Draetta G.F., Alcalay M., Seiser C., and Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell. Biol. 27 (2007) 4784-4795
54. Keshelava N., Davicioni E., Wan Z., Ji L., Sposto R., Triche T.J., and Reynolds C.P. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J. Natl. Cancer Inst. 99 (2007) 1107-1119
55. Pulukuri S.M., Gorantla B., and Rao J.S. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J. Biol. Chem. 282 (2007) 35594-35603
56. Deubzer H.E., Ehemann V., Westermann F., Heinrich R., Mechtersheimer G., Kulozik A.E., Schwab M., and Witt O. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int. J. Cancer 122 (2008) 1891-1900
57. Deubzer H.E., Ehemann V., Kulozik A.E., Westermann F., Savelyeva L., Kopp-Schneider A., Riester D., Schwab M., and Witt O. Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett. (2008)
58. Oh M., Choi I.K., and Kwon H.J. Inhibition of histone deacetylase1 induces autophagy. Biochem. Biophys. Res. Commun. 369 (2008) 1179-1183
59. Inoue S., Mai A., Dyer M.J., and Cohen G.M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66 (2006) 6785-6792
60. Huang B.H., Laban M., Leung C.H., Lee L., Lee C.K., Salto-Tellez M., Raju G.C., and Hooi S.C. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12 (2005) 395-404
61. Harms K.L., and Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67 (2007) 3145-3152
62. Bicaku E., Marchion D.C., Schmitt M.L., and Munster P.N. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res. 68 (2008) 1513-1519
63. I. Oehme, H.E. Deubzer, D. Wegener, D. Pickert, J.P. Linke, B. Hero, A. Kopp-Schneider, F. Westermann, S.M. Ulrich, A. Von Deimling, M. Fischer, O. Witt, Histone deacetylase 8 in neuroblastoma tumorigenesis, Clin. Cancer Res. in press.
64. Zimmermann S., Kiefer F., Prudenziati M., Spiller C., Hansen J., Floss T., Wurst W., Minucci S., and Gottlicher M. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res. 67 (2007) 9047-9054
65. Atsumi A., Tomita A., Kiyoi H., and Naoe T. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARα as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem. Biophys. Res. Commun. 345 (2006) 1471-1480
66. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., Downing J.R., Meyers S., and Hiebert S.W. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21 (2001) 6470-6483
67. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., Chakravarty P., Paolini C., De Francesco R., Gallinari P., Steinkuhler C., and Di Marco S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA 101 (2004) 15064-15069
68. Lee H., Sengupta N., Villagra A., Rezai-Zadeh N., and Seto E. Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol. Cell. Biol. 26 (2006) 5259-5269
69. Balasubramanian S., Ramos J., Luo W., Sirisawad M., Verner E., and Buggy J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia (2008)
70. Chauchereau A., Mathieu M., de Saintignon J., Ferreira R., Pritchard L.L., Mishal Z., Dejean A., and Harel-Bellan A. HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene 23 (2004) 8777-8784
71. Qian D.Z., Kachhap S.K., Collis S.J., Verheul H.M., Carducci M.A., Atadja P., and Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. Cancer Res. 66 (2006) 8814-8821
72. Watamoto K., Towatari M., Ozawa Y., Miyata Y., Okamoto M., Abe A., Naoe T., and Saito H. Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene 22 (2003) 9176-9184
73. Mottet D., Bellahcene A., Pirotte S., Waltregny D., Deroanne C., Lamour V., Lidereau R., and Castronovo V. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ. Res. 101 (2007) 1237-1246
74. Sakuma T., Uzawa K., Onda T., Shiiba M., Yokoe H., Shibahara T., and Tanzawa H. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol. 29 (2006) 117-124
75. Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., Mita K., Hamaguchi M., Hayashi S., and Iwase H. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. 10 (2004) 6962-6968
76. Saji S., Kawakami M., Hayashi S., Yoshida N., Hirose M., Horiguchi S., Itoh A., Funata N., Schreiber S.L., Yoshida M., and Toi M. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24 (2005) 4531-4539
77. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100 (2003) 4389-4394
78. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., and Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280 (2005) 26729-26734
79. Li Y., Zhang X., Polakiewicz R.D., Yao T.P., and Comb M.J. HDAC6 is required for EGF-induced β-catenin nuclear localization. J. Biol. Chem. (2008)
80. Park J.H., Kim S.H., Choi M.C., Lee J., Oh D.Y., Im S.A., Bang Y.J., and Kim T.Y. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. 368 (2008) 318-322
81. Shan B., Yao T.P., Nguyen H.T., Zhuo Y., Levy D.R., Klingsberg R.C., Palmer M.L., Holder K.N., and Lasky J.A. Requirement of HDAC6 for TGF-β 1-induced epithelial-mesenchymal transition. J. Biol. Chem. (2008)
82. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
83. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
84. Grant S., Easley C., and Kirkpatrick P. Vorinostat. Nat. Rev. Drug Discov. 6 (2007) 21-22
85. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
86. Nielsen T.K., Hildmann C., Dickmanns A., Schwienhorst A., and Ficner R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol. 354 (2005) 107-120
87. Sternson S.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. 3 (2001) 4239-4242
88. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409 (2008) 581-589
89. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., and Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62 (2002) 4916-4921
90. Kijima M., Yoshida M., Sugita K., Horinouchi S., and Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268 (1993) 22429-22435
91. Hu E., Dul E., Sung C.M., Chen Z., Kirkpatrick R., Zhang G.F., Johanson K., Liu R., Lago A., Hofmann G., Macarron R., de los Frailes M., et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307 (2003) 720-728
92. Perez-Balado C., Nebbioso A., Rodriguez-Grana P., Minichiello A., Miceli M., Altucci L., and de Lera A.R. Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J. Med. Chem. 50 (2007) 2497-2505
93. Witter D.J., Harrington P., Wilson K.J., Chenard M., Fleming J.C., Haines B., Kral A.M., Secrist J.P., and Miller T.A. Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett. 18 (2008) 726-731
94. Arts J., Angibaud P., Marien A., Floren W., Janssens B., King P., van Dun J., Janssen L., Geerts T., Tuman R.W., Johnson D.L., Andries L., et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br. J. Cancer 97 (2007) 1344-1353
95. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97 (2000) 10014-10019
96. Han J.W., Ahn S.H., Park S.H., Wang S.Y., Bae G.U., Seo D.W., Kwon H.K., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60 (2000) 6068-6074
97. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., and Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96 (1999) 4592-4597
98. Archer S.Y., Meng S., Shei A., and Hodin R.A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 95 (1998) 6791-6796
99. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63 (2003) 3637-3645
100. Jaboin J., Wild J., Hamidi H., Khanna C., Kim C.J., Robey R., Bates S.E., and Thiele C.J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62 (2002) 6108-6115
101. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S., Sklenar A.R., Davis M.E., Lucas D.M., Fischer B., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105 (2005) 959-967
102. Gui C.Y., Ngo L., Xu W.S., Richon V.M., and Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101 (2004) 1241-1246
103. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., Sun J., Yu Y., Zhou W., Zheng Q., Wu M., Otterson G.A., et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol. Cell. Biol. 26 (2006) 2782-2790
104. Wu L.P., Wang X., Li L., Zhao Y., Lu S., Yu Y., Zhou W., Liu X., Yang J., Zheng Z., Zhang H., Feng J., et al. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol. Cell. Biol. 28 (2008) 3219-3235
105. Gore L., Rothenberg M.L., O'Bryant C.L., Schultz M.K., Sandler A.B., Coffin D., McCoy C., Schott A., Scholz C., and Eckhardt S.G. A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 14 (2008) 4517-4525
106. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23 (2005) 3912-3922
107. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., Tidwell M.L., Greer J., Chung E.J., Lee M.J., Gore S.D., Sausville E.A., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109 (2007) 2781-2790
108. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., Panageas K., Wright J.J., Pandolfi P.P., and Nimer S.D. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14 (2008) 826-832
109. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., Hancox A., Hong J.A., Chen G.A., Kruchin E., Wright J.J., Rosing D.R., et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin. Cancer Res. 14 (2008) 188-198
110. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., Brooks R., Piekarz R.L., Tucker E., Figg W.D., Chan K.K., Goldspiel B., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228,NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8 (2002) 718-728
111. Fouladi M., Furman W.L., Chin T., Freeman III B.B., Dudkin L., Stewart C.F., Krailo M.D., Speights R., Ingle A.M., Houghton P.J., Wright J., Adamson P.C., et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a children's oncology group report. J. Clin. Oncol. 24 (2006) 3678-3685
112. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V.R., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2008) 1060-1066
113. Siu L.L., Pili R., Duran I., Messersmith W.A., Chen E.X., Sullivan R., MacLean M., King S., Brown S., Reid G.K., Li Z., Kalita A.M., et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 26 (2008) 1940-1947
114. Piekarz R.L., Frye A.R., Wright J.J., Steinberg S.M., Liewehr D.J., Rosing D.R., Sachdev V., Fojo T., and Bates S.E. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin. Cancer Res. 12 (2006) 3762-3773
115. Krennhrubec K., Marshall B.L., Hedglin M., Verdin E., and Ulrich S.M. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 2874-2878
116. Tran A.D., Marmo T.P., Salam A.A., Che S., Finkelstein E., Kabarriti R., Xenias H.S., Mazitschek R., Hubbert C., Kawaguchi Y., Sheetz M.P., Yao T.P., et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J. Cell Sci. 120 (2007) 1469-1479
117. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., and Anderson K.C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA 102 (2005) 8567-8572
118. Suzuki T., Kouketsu A., Itoh Y., Hisakawa S., Maeda S., Yoshida M., Nakagawa H., and Miyata N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem. 49 (2006) 4809-4812
119. Itoh Y., Suzuki T., Kouketsu A., Suzuki N., Maeda S., Yoshida M., Nakagawa H., and Miyata N. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J. Med. Chem. 50 (2007) 5425-5438
120. Kozikowski A.P., Chen Y., Gaysin A., Chen B., D'Annibale M.A., Suto C.M., and Langley B.C. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J. Med. Chem. 50 (2007) 3054-3061
121. Mai A., Massa S., Pezzi R., Simeoni S., Rotili D., Nebbioso A., Scognamiglio A., Altucci L., Loidl P., and Brosch G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 48 (2005) 3344-3353
122. Jones P., Bottomley M.J., Carfi A., Cecchetti O., Ferrigno F., Lo Surdo P., Ontoria J.M., Rowley M., Scarpelli R., Schultz-Fademrecht C., and Steinkuhler C. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 18 (2008) 3456-3461